二重特異性抗体の世界市場予測

◆英語タイトル:Global Bi-Specific Antibodies Market Forecast to 2022
◆商品コード:RNCS80303
◆発行会社(リサーチ会社):RNCOS
◆発行日:2018年2月16日
◆ページ数:80
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Multi UserUSD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Bi-specific antibody is one of the most potentially powerful tools which have emerged in the biopharmaceutical industry. The bi-specific antibodies intend to provide the next generation of targeted biologics by engaging two different targets simultaneously. These drugs offer several advantages over traditional treatment options for various diseases such as cancer. They have fewer side effects due to high specificity towards disease target. These antibodies are of particular importance for patients who experience recurrence or resistance to drugs.
According to the RNCOS report entitled “Global Bi-Specific Antibodies Market Forecast to 2022”, the Global Bi-Specific Antibodies Market is anticipated to witness a double digit growth during the forecast period. The report provides information about the current and future scenario of this market. The report also highlights the major drivers, such as increasing incidences of diseases and increasing demand for effective treatment, for the Global Bi-Specific Antibodies Market. Furthermore, the report also gives information related to the commercially available bi-specific antibody drugs.

Moreover, few hindrances, such as production hurdles and regulatory challenges, which are slowing down the growth of the Global Bi-Specific Antibodies Market, have also been mentioned in the report. In addition, the report also highlights various trends and developments taking place in this market.

Furthermore, in this report, we have structured the information regarding bi-specific antibodies at various stages of clinical development. The pipeline chapter provides in depth analysis of bi-specific antibodies by clinical phase, indications for which they are being developed, and technology. Additionally, the study provides all-inclusive current analysis of various bi-specific antibodies in advanced as well as early stages of development. Moreover, our report places emphasis on the strategic collaborations that can impact industry’s growth.

The prominent players in Global Bi-Specific Antibodies Market have been discussed in the last section of the report. A brief business overview and financial information about each of these players has been provided, along with their product portfolios, product pipeline and recent developments. Overall, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the Global Bi-Specific Antibodies Market.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. Bi-Specific Antibodies – An Introduction
4. Global Bi-Specific Antibodies Market Outlook to 2022
4.1 BLINCYTO
4.2 Hemlibra
4.3 Removab
5. Bi-Specific Antibodies Pipeline Analysis
5.1 By Clinical Phase
5.2 By Indication
5.3 By Technology
6. Market Dynamics
6.1 Drivers
6.1.1 Rising Global Cancer Epidemics
6.1.2 Bi-Specific Antibodies Improving the Targeting Capabilities of Traditional mAbs
6.1.3 T-cells in Bi-Specific Antibodies Mediated Immunotherapy
6.1.4 Increasing Demand for Bi-Specific/Double Barreled Antibodies
6.2 Challenges
6.2.1 Production Hurdles in Bi-Specific Antibodies Development
6.2.2 Regulatory Challenges
7. Current Status of Major Bi-Specific Antibodies in Pipeline
7.1 BLINCYTO/Blinatumomab – Amgen Inc.
7.2 ABT-122 – AbbVie Inc.
7.3 MCLA-128 – Merus N.V.
7.4 ALX-0761/M1095 – Ablynx
7.5 MGD006/S80880 – MacroGenics, Inc.
7.6 ZW25 – Zymeworks Inc.
8. Trends and Developments
8.1 Bi-specific Antibody Application for Tumor Therapy
8.2 Bi-specific Antibodies Development Against Myeloma
8.3 Bi-specific Antibody Agreement with EpimAb Biotherapeutics
8.4 B-specific Antibody Development against Multiple Ebola viruses
9. Strategic Collaborations in the Bi-Specific Antibodies Industry
10. Competitive Assessment
10.1 Amgen Inc.
10.2 F. Hoffman La Roche Ltd.
10.3 AbbVie Inc.
10.4 OncoMed Pharmaceuticals, Inc.
10.5 Glenmark Pharmaceuticals Limited
10.6 Xencor, Inc.
10.7 MacroGenics, Inc.
10.8 Aptevo Therapeutics Inc.
10.9 Ligand Pharmaceuticals, Inc.
10.10 Regeneron Pharmaceuticals, Inc.
10.11 Fresenius SE & Co. KGaA
10.12 Merus N.V.

List of Figures:

Figure 3-1: Bi-Specific Antibodies – Mechanism of Action
Figure 4-1: Global – Bi-Specific Antibodies Market (Million US$), 2016-2022
Figure 4-2: Global – BLINCYTO Sales (Million US$), 2016 & 2017
Figure 5-1: Global – Bi-Specific Antibodies Pipeline by Clinical Phase (%), 2017
Figure 5-2: Global – Bi-Specific Antibodies Pipeline by Indication (%), 2017
Figure 5-3: Global – Bi-Specific Antibodies Pipeline by Technology (%), 2017
Figure 6-1: Global – Cancer & Other Non-Communicable Disease Epidemics (%), 2016
Figure 10-1: Amgen Inc. – Breakup of Revenue by Geography (%), 2016
Figure 10-2: F. Hoffman La Roche Ltd. – Breakup of Group Sales by Business Segments (%), 2016
Figure 10-3: F. Hoffman La Roche Ltd. – Breakup of Group Sales by Geography (%), 2016
Figure 10-4: AbbVie Inc. – Breakup of Net Revenues by Geography (%), 2016
Figure 10-5: Glenmark Pharmaceuticals Limited – Breakup of Revenue by Geography (%), FY2017
Figure 10-6: Xencor, Incl. – Breakup of Revenue by Product Programs (%), 2016
Figure 10-7: Ligand Pharmaceuticals, Inc. – Breakup of Revenue by Operations (%), 2016
Figure 10-8: Ligand Pharmaceuticals, Inc. – Breakup of Royalty Revenue by Program (%), 2016
Figure 10-9: Ligand Pharmaceuticals, Inc. – Breakup of Material Sales by Use (%), 2016
Figure 10-10: Fresenius SE & Co. KGaA – Breakup of Sales by Business Segments (%), 2016
Figure 10-11: Fresenius SE & Co. KGaA – Breakup of Sales by Geography (%), 2016

List of Tables:

Table 4-1: Global – Potential Patients for BLINCYTO (2017)
Table 4-2: Global – Potential Patients for BLINCYTO (2020)
Table 4-3: Global – Major Ongoing Trials for BLINCYTO
Table 5-1: Global – Major Bi-Specific Antibodies in Pipeline
Table 9-1: Global – Major Strategic Collaborations in the Bi-Specific Antibodies Industry
Table 10-1: Top Companies by Bi-Specific Antibodies in Pipeline
Table 10-2: Amgen Inc. – Product Portfolio
Table 10-3: Amgen Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-4: Amgen Inc. – Key Financials (Million US$), 2014-2016
Table 10-5: F. Hoffman La Roche Ltd. – Major Bi-Specific Antibodies in Pipeline
Table 10-6: F. Hoffman La Roche Ltd. – Key Financials (Million US$), 2014-2016
Table 10-7: AbbVie Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-8: AbbVie Inc. – Key Financials (Million US$), 2014-2016
Table 10-9: OncoMed Pharmaceuticals, Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-10: OncoMed Pharmaceuticals, Inc. – Key Financials (Million US$), 2014-2016
Table 10-11: Glenmark Pharmaceuticals Limited – Major Bi-Specific Antibodies in Pipeline
Table 10-12: Glenmark Pharmaceuticals Limited – Key Financials (Million US$), FY2015-FY2017
Table 10-13: Xencor, Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-14: Xencor, Inc. – Key Financials (Million US$), 2014-2016
Table 10-15: MacroGenics, Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-16: MacroGenics, Inc. – Key Financials (Million US$), 2014-2016
Table 10-17: Aptevo Therapeutics – Major Bi-Specific Antibodies in Pipeline
Table 10-18: Aptevo Therapeutics Inc. – Key Financials (Million US$), 2015-2016
Table 10-19: Ligand Pharmaceuticals, Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-20: Ligand Pharmaceuticals, Inc. – Key Financials (Million US$), 2014-2016
Table 10-21: Regeneron Pharmaceuticals, Inc. – Major Bi-Specific Antibodies in Pipeline
Table 10-22: Regeneron Pharmaceuticals, Inc. – Key Financials (Million US$), 2015-2017
Table 10-23: Fresenius SE & Co. KGaA – Product Portfolio
Table 10-24: Fresenius SE & Co. KGaA – Key Financials (Million US$), 2014-2016
Table 10-25: Merus N.V. – Major Bi-Specific Antibodies in Pipeline



【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 二重特異性抗体の世界市場予測(Global Bi-Specific Antibodies Market Forecast to 2022)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆